Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: Lessons to avoid repeating past errors

European Respiratory Journal

Volumn 49, Issue 3, 2017, Pages

  Veziris, Nicolas ^a,b   Bernard, Christine ^a,b   Guglielmetti, Lorenzo ^a,b,c   Le Du, Damien ^c   Marigot Outtandy, Dhiba ^c,d   Jaspard, Marie ^b   Caumes, Eric ^b   Lerat, Isabelle ^e   Rioux, Christophe ^e   Yazdanpanah, Yazdan ^e,f,g   Tiotiu, Angelica ^h   Lemaitre, Nadine ⁱ   Brossier, Florence ^a,b   Jarlier, Vincent ^a,b   Robert, Jerome ^a,b   Sougakoff, Wladimir ^a,b   Aubry, Alexandra ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Centre Hospitalier de Bligny   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

^f UNIVERSITÉ PARIS DIDEROT   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECT; ISOLATION AND PURIFICATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85026874812     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01719-2016     Document Type: Letter

References (15)

1. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723–732.
2. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188–194.
3. Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564–574.
4. Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9: e102135.
5. Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015; 45: 554–557.
6. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979–2981.
7. Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2016; 60: 4590–4599.
8. Veziris N, Martin C, Brossier F, et al. Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur J Clin Microbiol Infect Dis 2007; 26: 423–425.
9. Bloemberg GV, Keller PM, Stucki D, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 2015; 373: 1986–1988.
10. Scardigli A, Caminero JA, Sotgiu G, et al. Efficacy and tolerability of ethionamide versus prothionamide: a systematic review. Eur Respir J 2016; 48: 946–952.
11. Lachâtre M, Rioux C, Le Dû D, et al. Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis 2016; 16: 294.
12. Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016; 48: 935–938.
13. Mordant P, Henry B, Morel S, et al. Chirurgie et tuberculose multi/ultrarésistante: une revue de la littérature réhabilite une intervention adjuvante à l’antibiothérapie chez des patients sélectionnés [Adjuvant surgical resection for multidrug-resistant tuberculosis: a review]. Rev Mal Respir 2014; 31: 511–524.
14. European Committee on Antimicrobial Susceptibility Testing. Clinical Breakpoints. www.eucast.org/clinical_breakpoints/ Date last accessed: April 5, 2016. Date last updated: January 2016.
15. US Food and Drug Administration. Anti-infective Drugs Advisory Committee Meeting Briefing Document. TMC207 (Bedaquiline): Treatment of Patients with MDR-TB. US Food and Drug Administration, 2012.